In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir

[1]  B. Weynand,et al.  Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment , 2023, Nature communications.

[2]  Y. Kawaoka,et al.  The accuracy of reverse genetics systems for SARS‐CoV‐2: Circular polymerase extension reaction versus bacterial artificial chromosome , 2023, Influenza and other respiratory viruses.

[3]  K. Matsumoto,et al.  Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo , 2023, The Journal of antimicrobial chemotherapy.

[4]  G. Oliva,et al.  Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease , 2023, Journal of Biological Chemistry.

[5]  T. Uehara,et al.  Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  J. Bukh,et al.  Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system , 2022, Science advances.

[7]  Seo Jung Hong,et al.  Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir , 2022, Nature.

[8]  Tadaki Suzuki,et al.  S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters , 2022, Science Translational Medicine.

[9]  R. Webby,et al.  Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents , 2022, Nature.

[10]  P. Maes,et al.  The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir , 2022, bioRxiv.

[11]  S. Moro,et al.  SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376 , 2022, Science Translational Medicine.

[12]  T. Sonoyama,et al.  Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults , 2022, Antimicrobial agents and chemotherapy.

[13]  Rommie E. Amaro,et al.  Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors , 2022, bioRxiv.

[14]  M. Torii,et al.  Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model , 2022, The Journal of antimicrobial chemotherapy.

[15]  Fereshteh Fallah Atanaki,et al.  Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites , 2022, Cell Host & Microbe.

[16]  T. Uehara,et al.  A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part , 2022, medRxiv.

[17]  A. Gribenko,et al.  Genetic Surveillance of SARS-CoV-2 Mpro Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid , 2022, bioRxiv.

[18]  Y. Orba,et al.  Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19 , 2022, Journal of medicinal chemistry.

[19]  Larissa B. Thackray,et al.  SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters , 2022, Nature.

[20]  A. Casadevall,et al.  Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis , 2022, Antiviral Research.

[21]  E. Callaway.  Heavily mutated Omicron variant puts scientists on alert , 2021, Nature.

[22]  M. C. Muenker,et al.  De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report , 2021, Nature Communications.

[23]  B. Weynand,et al.  The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern , 2021, Nature Communications.

[24]  Malina A. Bakowski,et al.  Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19 , 2021, Nature Communications.

[25]  K. Gajiwala,et al.  An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 , 2021, Science.

[26]  D. O’Connor,et al.  Characterization of a new SARS-CoV-2 variant that emerged in Brazil , 2021, Proceedings of the National Academy of Sciences.

[27]  Tsuyoshi Sekizuka,et al.  Disentangling primer interactions improves SARS-CoV-2 genome sequencing by multiplex tiling PCR , 2020, PloS one.